Document Detail


An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. Sustained-Release Dexfenfluramine Study Group.
MedLine Citation:
PMID:  9731088     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: The appetite-suppressant drug fenfluramine, usually given in combination with phentermine, has been reported to be associated with cardiac valvular regurgitation. Concern has been raised that the d-enantiomer of fenfluramine, dexfenfluramine, may also cause this problem. We were able to study the question by modifying an ongoing trial comparing dexfenfluramine with regular dexfenfluramine and placebo. METHODS: We modified our randomized, double-blind, placebo-controlled study of dexfenfluramine to include echocardiographic examinations of 1072 overweight patients within a median of one month after the discontinuation of treatment. The patients (approximately 80 percent of whom were women) had been randomly assigned to receive dexfenfluramine (366 patients), investigational sustained-release dexfenfluramine (352 patients), or placebo (354 patients). The average duration of treatment was 71 to 72 days in each of the three groups. Echocardiograms were assessed in a blinded fashion. RESULTS: When all degrees of valvular regurgitation were considered and when the two dexfenfluramine groups were combined, there was a higher prevalence of any degree of aortic regurgitation (17.0 percent vs. 11.8 percent, P=0.03) and any degree of mitral regurgitation (61.4 percent vs. 54.4 percent, P=0.01) in the active-treatment groups than in the placebo group. These differences were primarily due to a higher prevalence of physiologic, trace, or mild regurgitation. Analyses that used the criteria of the Food and Drug Administration for aortic regurgitation of mild or greater severity and mitral regurgitation of moderate or greater severity found no statistically significant difference among the groups (P=0.14 to 0.75). These analyses showed that aortic regurgitation of mild or greater severity occurred in 5.0 percent of the patients in the dexfenfluramine group, 5.8 percent of those in the sustained-release dexfenfluramine group, 5.4 percent of those in the two active-treatment groups combined, and 3.6 percent of those in the placebo group. Mitral regurgitation of moderate or greater severity occurred in 1.7, 1.8, 1.8, and 1.2 percent, respectively. Aortic regurgitation of mild or greater severity, mitral regurgitation of moderate or greater severity, or both occurred in 6.5 percent, 7.3 percent, 6.9 percent, and 4.5 percent, respectively. CONCLUSIONS: The increased prevalence of aortic and mitral regurgitation in patients treated with dexfenfluramine was small, and the degree of regurgitation was usually classified as physiologic, trace, or mild. However, the duration of therapy was short, and whether therapy of longer duration would yield the same or different results is not known.
Authors:
N J Weissman; J F Tighe; J S Gottdiener; J T Gwynne
Related Documents :
877638 - Bleeding, clotting, and functional disability following beall prosthetic mitral valve r...
12595858 - Outcome of significant functional tricuspid regurgitation after percutaneous mitral val...
21095338 - Anterior mitral leaflet length: predictor for mitral valve repair in a rheumatic popula...
17912528 - A prospective randomized comparative study on the use of ventral subcutaneous flap to p...
21468328 - Complete healing of chronic wounds of a lower leg with haemoglobin spray and regenerati...
14747118 - The role of coronary angiography in acute type a aortic dissection.
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  The New England journal of medicine     Volume:  339     ISSN:  0028-4793     ISO Abbreviation:  N. Engl. J. Med.     Publication Date:  1998 Sep 
Date Detail:
Created Date:  1998-09-15     Completed Date:  1998-09-15     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0255562     Medline TA:  N Engl J Med     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  725-32     Citation Subset:  AIM; IM    
Affiliation:
Division of Cardiology and the Cardiovascular Institute, Georgetown University Medical Center, Washington, DC 20007-2197, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aortic Valve / pathology,  ultrasonography
Aortic Valve Insufficiency / chemically induced*,  classification,  ultrasonography
Appetite Depressants / administration & dosage,  adverse effects*
Blood Pressure
Delayed-Action Preparations
Double-Blind Method
Female
Fenfluramine / administration & dosage,  adverse effects*
Humans
Male
Middle Aged
Mitral Valve / pathology,  ultrasonography
Mitral Valve Insufficiency / chemically induced*,  classification,  ultrasonography
Obesity / complications,  drug therapy*,  pathology
Prevalence
Pulmonary Artery / physiology
Chemical
Reg. No./Substance:
0/Appetite Depressants; 0/Delayed-Action Preparations; 458-24-2/Fenfluramine
Comments/Corrections
Comment In:
N Engl J Med. 1998 Sep 10;339(11):765-6   [PMID:  9731094 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation.
Next Document:  Endogenous hormones and the risk of hip and vertebral fractures among older women. Study of Osteopor...